
UCSF team's method for assessing brain injuries could transform concussion care
A team of neurologists led by UCSF scientists has developed a new scale for assessing damage caused by brain trauma that could overhaul the field of concussion medicine and help doctors better treat patients with both the least and most severe injuries, including those who are comatose and considered near-death.
Health providers have been using the Glasgow Coma Scale to assess brain injuries for more than 50 years. The tool assigns patients a score based on their physical presentation, including how alert they are, whether they can speak clearly and how they respond to pain, and that score determines if their injury is mild, moderate or severe. But experts in neurology have long said that it is a blunt instrument for assessing complex injuries.
The new tool, described in a paper published Tuesday in the journal Lancet Neurology, uses the Glasgow Coma Scale along with other descriptors — including head scans, blood tests and the patient's own background — to quickly produce a more nuanced and, neurologists say, accurate analysis of a brain injury.
'Mild, moderate and severe doesn't work for any disease,' said Dr. Geoff Manley, chief of neurosurgery at San Francisco General Hospital and lead author of the new paper. 'We need to characterize these patients better. Our hope is that changing the framework of how we describe these patients can hopefully change the culture.'
Worldwide, head injuries are among the most common causes of disability and death. Nearly 50 million people sustain a brain injury each year, and in the United States about 70,000 people die annually from head wounds.
And increasingly, concussions and other so-called minor head injuries are understood to be potentially disastrous for some people. Such injuries have become the hallmark of modern warfare, and are of mounting concern in sports like football and soccer.
The new framework will provide 'more granularity and allow us to have more thoughtful conversations with our patients,' said Dr. Cathra Halabi, director of UCSF's neurorecovery clinic.
'We're in a very exciting time where there's a confluence of pretty rapid advances in neuroscience and rapid advances in technology,' Halabi said. 'And we're now at a point where we can leverage that and focus on our patients and what is going to serve them best.'
The Glasgow Coma Scale lumps patients broadly into mild, moderate and severe categories, with 'mild' fitting those who are able to talk normally and understand where they are and what's going on, and 'severe' including those who are comatose or otherwise nonresponsive. But those categories don't capture the complexity of injury, especially at the mild and severe ends of the spectrum.
In fact, some patients with so-called minor head wounds suffer debilitating symptoms months after their injuries, including difficulty concentrating, chronic headaches, insomnia, and depression and anxiety.
Meanwhile, some coma patients considered near-death based on the Glasgow Coma Scale — including people whose families were advised to remove them from life support — are able to make a near-full recovery.
'These terms weren't doing patients any favors,' said Manley, who has experience treating both the least and most severe cases, including the 2002 case of a San Francisco police officer who fully recovered from an injury that had him in a coma.
'We were quite nihilistic' about the severe cases, Manley said, but anecdotal experience and, later, research studies found that some of those patients weren't as bad off as they appeared and could recover — if not completely, then enough to have some independence.
At the same time, 'we didn't pay much attention to these people with mild traumatic brain injury,' Manley said. 'I was following up with people in the emergency department who were like, 'You said I was stable but it's been three months and I'm not back at work.''
The new scale, called the CBI-M framework, takes clinical, blood biomarker and imaging results into account, along with modifiers such as the patient's mental health, pre-existing conditions, housing status and other social determinants of health.
The framework will still rely on the Glasgow Coma Scale — that's the clinical element of CBI-M — but the other factors should give a more robust sense of how injured patients are and their prognosis.
For example, a patient who hit his head in a car accident may show up in the emergency room fairly alert and with a high score on the Glasgow Coma Scale, suggesting a mild brain injury. If that coma scale is the only tool used — which is often the case — that patient may be sent home within hours.
But a blood test may show high biomarker levels, suggesting a more serious injury, which would then prompt doctors to do a brain scan, which could show a blood clot or bleeding. In addition, the patient may have substance abuse issues that may interfere with recovery and should be taken into consideration. So that patient may stay overnight, or be referred to another clinic for follow-up care.
On the other end of the spectrum, a comatose patient with a very low Glasgow Coma Scale, suggesting a very poor prognosis, but who also has low biomarker levels, no alarming signs on a brain scan and no modifying issues that could impede recovery may wake up and do well.
'The old way of categorizing brain injury was a very blunt, crude way,' said Dr. Anthony DiGiorgio, a UCSF neurosurgeon who was not involved in the Lancet paper. 'This tool makes us able to hedge on one side or the other and help manage expectations. It's a lot easier for me to figure out how to triage a patient.'
The new tool also should be applied to research into head injuries, which has been frustratingly slow and stilted, Manley said. There are no drugs specifically to treat head injuries, and neurologists say that's at least in part because scientists have struggled to stratify patients in a way that makes testing effective.
The 'mild,' 'moderate' and 'severe' head injury clusters that scientists have used to study therapies aren't very homogenous, as demonstrated by biomarker results, head scans and practical outcomes. Drugs to treat mild injury may have failed, for example, because 'mild' includes a broad array of symptoms and manifestations — maybe those drugs worked on some people with mild injury but not others.
'We've had numerous unsuccessful drug trials, and I think a large part of that is because of the heterogenous nature of brain injury,' DiGiorgio said. 'Maybe down the line we can get some useful clinical trials out of this framework.'
Rolling out the new brain injury tool will likely take 10 years at least, Manley and others said. San Francisco General Hospital already uses aspects of the new tool, including taking patients' background into consideration when evaluating head injuries. And Manley said the tool already is being used in some clinical trials.
Sean Sanford, 43, has firsthand experience on both ends of the brain injury spectrum, including a prolonged recovery from what seemed like a mild skateboarding accident eight years ago.
He was just 20 for the first injury, which occurred in a car accident in his hometown of Grass Valley (Nevada County). He was in a coma for weeks, and his outlook was grim; his family was told he might not wake up. But he managed to fully recover.
The second injury was 15 years later, when Sanford was skating with some friends in Glen Park. He hit his head on a ledge and knocked himself out. He came around after a few seconds, but his friends took him to the emergency room when he was behaving oddly and couldn't seem to remember where he was or what he was doing.
At San Francisco General Hospital, he was told it was probably a minor head injury, but doctors decided to do a brain scan just in case — Sanford was rushed into surgery when the scan showed a skull fracture and bleeding. His friends and wife were told that if he 'had gone home and gone to sleep, he wouldn't have woken up,' Sanford recalled.
The recovery from that injury has been rougher than the first time around, for reasons that aren't entirely clear. Sanford developed a seizure disorder and is on medication for that now. He had to take time off college, though he's since graduated and is working toward his master's degree in creative writing.
'The insomnia is still a thing. And I get anxiety,' Sanford said of the lingering symptoms. He struggles with short-term memory and concentration. 'Sometimes I feel like the subjects in my brain are just like a pinball bouncing around.'
But he's also grateful both for the care he got and for the awareness of the nature of his injury. He said it would be incredibly frustrating to deal with the ongoing symptoms if he'd been told his was a 'mild' injury and left on his own. But he's had follow-up care, including therapy to manage his anxiety, and his family and friends too have been supportive.
'One of the big things they told me that I have to keep reminding myself is it's going to be a long road to recovery,' Sanford said. 'Don't get discouraged. Don't feel like you're broken. But it will be years, if not decades, before you even feel normal again, and you might never feel normal again.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Gizmodo
2 days ago
- Gizmodo
Smoking Weed and Eating Edibles Share This Surprising Health Risk
A new study has found a startling link between chronic cannabis use and increased risk of cardiovascular disease—regardless of whether you smoke it or consume edibles. The finding challenges commonly held beliefs about the health impacts of tetrahydrocannabinol (THC), which many see as a relatively harmless drug—especially when ingested. The study, published Wednesday, May 28 in the journal JAMA Cardiology, found that THC smokers suffer from significantly worse artery function than non-users. They observed the same effect in edible consumers, though their arteries were not as severely affected. In either case, vascular function was reduced by roughly half compared to those who do not use cannabis, according to a statement from the University of California, San Francisco. 'Scientifically, this THC result is really interesting but boy does it screw up the public health messaging,'' co-author Matt Springer, a cardiovascular researcher at UCSF, reportedly said to lead author and UCSF physician-scientist Leila Mohammadi when he saw the data. These results add to a growing body of evidence that suggests long-term weed use can lead to cardiovascular damage and life-threatening events such as heart attacks and strokes, though experts still lack consensus on its precise impacts. A 2024 study published in the Journal of the American Heart Association found that people who consume cannabis daily had a 25% increased risk of heart attack and a 42% increased risk of stroke compared to non-users. For this new study, researchers investigated how cannabis impacts vascular function. To isolate the effects of chronic cannabis use, they recruited 55 otherwise healthy adults aged 18 to 50 who did not use any form of nicotine and were not frequently exposed to secondhand smoke. These participants were sorted into three groups: marijuana smokers, edible users, and non-users. Those in the two cannabis user groups reported taking the drug at least three times per week, either exclusively through smoking or edibles. To assess the participants' vascular function, the researchers measured dilation of the brachial artery—located in the upper arm—to determine whether it could properly expand in response to increased blood flow. To that end, they used an inflatable forearm cuff to briefly block blood flow to the artery, then used ultrasound to measure its diameter before and after inflating the cuff. Matt Springer, a cardiovascular researcher at UCSF whose lab led the study, told Live Science that his test offers a 'window into the future.' When blood vessels cannot fully dilate, he said, the risk of heart attack and other poor cardiovascular outcomes increases. Participants who did not consume cannabis showed an average vessel dilation—represented as the percent change from the baseline measurement of artery diameter—of 10.4%. This value was significantly reduced among weed smokers and edible users, who showed an average vessel dilation of 6.0% and 4.6%, respectively. For reference, average values for brachial artery dilation in healthy individuals typically range from 8.0% to 15%. In a previous study, Springer's lab found similarly reduced levels of vessel dilation among e-cigarette and cigarette smokers. To better understand how THC causes this change, the researchers ran lab tests to determine how endothelial cells—which form the linings of blood vessels and release nitric oxide to trigger dilation—responded to the participants' blood samples. These tests revealed that the blood of chronic cannabis smokers inhibited nitric oxide production in the cells, which may explain why these participants showed reduced vessel dilation. This effect was not observed in edible consumers, however, suggesting that ingestible THC may impact arterial function via an entirely separate mechanism. Figuring out what that mechanism may be will require further research. What's more, subsequent studies will need to reproduce these findings in a larger population to validate the results. Within the last several years, cannabis use among U.S. adults has reached new heights, according to the NIH's National Institute on Drug Abuse. As such, investigating the health effects of THC is more important than ever before—especially as mounting evidence challenges perceptions of weed as a harmless high.

Associated Press
7 days ago
- Associated Press
Rosenman Symposium 2025 Brings National Healthcare Innovation to UCSF
A signature UCSF event, the symposium convenes top minds to address cost, equity, and the future of care 'Our theme this year was Healthcare in Harmony. Not because harmony is impossible, but because it's essential. When innovation, cost, and care are in sync, everyone benefits.'— Christine Winoto, Executive Director of the UCSF Rosenman Institute SAN FRANCISCO, CA, UNITED STATES, May 30, 2025 / / -- On May 20–21, the UCSF Rosenman Institute hosted the 9th Annual Rosenman Symposium at UCSF Mission Bay—two days of raw, candid, and solution-driven conversations on the future of healthcare. The Rosenman Institute at UCSF, one of the world's leading health sciences institutions, exists to convene, connect, and catalyze—bringing national voices together to inspire breakthrough solutions and foster lasting partnerships. UCSF faculty and leaders played central roles in helping shape the dialogue on cost, equity, and innovation. 'UCSF is a place where innovation, research, and care come together every day,' said Christine Winoto, Executive Director of the UCSF Rosenman Institute. 'This symposium reflects that spirit, connecting leaders from across the healthcare ecosystem so we can shape what's next together. Our theme this year was Healthcare in Harmony. Not because harmony is impossible, but because it's essential. When innovation, cost, and care are in sync, everyone benefits.' Discussions spanned a wide range of intersecting issues, including the $9 trillion forecast for U.S. healthcare spending, equity gaps, women's heart health, the future of cancer therapy and the cost, and behavioral health. Throughout, participants explored how to design healthcare that is not only innovative and cost-effective, but also inclusive, measurable, and accountable. The Rosenman Institute brought forward impactful topics and created space for participants to think differently. By challenging assumptions and surfacing new perspectives, the symposium encouraged everyone, from entrepreneurs and UCSF Health leaders to broader healthcare industry decision makers and stakeholders, to approach problems in new ways. The goal: to spark solutions that reshape how we address the most pressing issues in healthcare. The Rosenman Institute, together with Blue Shield of California and Kaiser Permanente, also honored Dr. Sandra Hernández, President and CEO of the California Health Care Foundation, with the 2025 UCSF Healthcare Impact Award, recognizing her decades-long leadership in advancing equity, public accountability, and access across the state. The symposium offered a unique opportunity to connect with healthcare stakeholders from payers and providers to investors, clinician-researchers, and innovators. As always, the Rosenman Symposium had no press, creating a rare space for honesty and breakthrough thinking. How Leaders Described the Symposium: 'The Rosenman Symposium is an outstanding opportunity to focus on the triangle of healthcare: quality, access, and affordability. Must we pick two, or is there a world where we can have all three? At Rosenman, the conversation is all about building a healthcare system that delivers on all three.' — Tom Insel, MD, Co-Founder Vanna Health and Benchmark Health, Former NIMH Director 'Each presentation was deeply empowering. I left the event better informed and more motivated to advocate for change.' — Karin Bartley, Blue Shield of California 'This is a symposium of ideas and innovation that brings together a diverse group of individuals who are at the forefront of what healthcare can be. It is the perfect place to be inspired, wowed, encouraged, and come out on the other end knowing that we have a lot of work to do and that with this community and this level of engagement there is a path forward.' — Fumi Mitsuishi, MD, Chief of Service, Psychiatry, ZSFG & Vice Chair for ZSFG, Professor of Medicine, UCSF 'The Rosenman Symposium is truly unique – it seamlessly balances deep policy insight with cutting-edge digital health innovation. The invite-only mix of top healthcare leaders sparked candid, strategic conversations I haven't experienced anywhere else.' — Lindsay Aspegren, Co-founder, North Coast Technology Investors Herminio Neto UCSF Rosenman Institute [email protected] Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
30-05-2025
- Yahoo
Smoking marijuana and eating cannabis gummies both linked to dangerous health risk, study finds
Long-term cannabis use in any form has been linked to a greater risk of heart disease. In a new study, researchers at UC San Francisco determined that eating edible cannabis, such as gummies, has the same impact on cardiovascular risk as smoking marijuana. The risk stems from reduced blood vessel function, according to the study, which was published in JAMA Cardiology on May 28. Heavy Cannabis Use Could Pose This Threat To The Brain The study included 55 people between 18 and 50 years of age who were "outwardly healthy." The participants were divided into three groups: those who regularly smoked marijuana, those who ate edibles containing THC (tetrahydrocannabinol), and those who didn't use cannabis, according to a UCSF press release. Read On The Fox News App The cannabis users had been consuming the substance at least three times weekly for at least one year. On average, the smokers had the habit for 10 years, while those consuming edibles had been doing so for five years, the release noted. In September 2024, the participants underwent testing to determine how well their blood vessels functioned and whether the cells lining the blood vessels were affected. Dementia Risk Connected To Cannabis-related Hospital Visits, Says Study All cannabis users were found to have "decreased vascular function," comparable to those who smoke tobacco. Their blood vessel function was roughly half compared to those who did not use cannabis. This side effect has been linked to a higher risk of heart attack, high blood pressure and other cardiovascular conditions, the researchers noted. The participants who smoked marijuana were also found to have changes in their blood serum that harmed cells lining their blood vessels and lymphatic vessels, an effect that was not seen in those who ate edible cannabis. The researchers noted that while smoking marijuana and consuming edibles both affect vascular function, they likely do so for different reasons. Shingles Vaccine Has Unexpected Effect On Heart Health "Chronic cannabis smoking and THC ingestion were associated with endothelial dysfunction [impaired functioning of the endothelial cells lining the inside of blood vessels] similar to that observed in tobacco smokers, although apparently occurring via distinct mechanisms," the researchers wrote. "This study enhances the understanding of the potential risks to vascular health linked to cannabis use and provides more evidence that cannabis use is not benign." Dr. Bradley Serwer, a Maryland-based cardiologist and chief medical officer at VitalSolution, an Ingenovis Health company that offers cardiovascular and anesthesiology services to hospitals nationwide, said he was not surprised by the study's findings. "We have known that the chronic use of THC-containing compounds can have negative health consequences — this study just reaffirms those prior studies," Serwer, who was not involved in the UCSF research, told Fox News Digital. The study did have some limitations. "Variability in cannabis strains complicates standardization," the researchers wrote. "Self-reported cannabis use may introduce recall bias; thus, participants were queried at multiple points: in the online survey, at the eligibility interview and before each visit." It was also challenging to determine whether blood vessel function could have also been affected by lifestyle factors like stress, caffeine and secondhand smoke exposure, they noted. Serwer pointed out that this was a "very small" study of only 55 people, all living in the San Francisco Bay area. "The study did not allow for variability in the different strains of cannabis, and they used a self-reporting survey, which can be under- or over-reported," he told Fox News Digital. "They looked for physiologic endpoints and not hard endpoints, such as heart attacks, strokes or death. We have to infer that the physiologic endpoints would result in cardiovascular events." Click Here To Sign Up For Our Health Newsletter The cardiologist said he agreed, however, with the conclusion that cannabis use is "not benign." "Chronic use does have potential cardiovascular risks," he warned. "There are therapeutic uses of cannabis, and the decision to use or avoid it should be made with all benefits and risks in mind." In general, Serwer said he cautions all of his patients to avoid any unnecessary cardiac risks. "As clinicians, we must weigh the benefits and the risks of a medicine/drug or intervention," he said. "If the risks outweigh the benefits, it should be avoided." For more Health articles, visit The study was funded mainly by the National Institute on Drug Abuse; the California Department of Cannabis Control; the California Tobacco-Related Disease Program; the National Heart, Lung, and Blood Institute; and the FDA Center for Tobacco Products. Fox News Digital reached out to cannabis industry organizations requesting article source: Smoking marijuana and eating cannabis gummies both linked to dangerous health risk, study finds